Revvity (RVTY) 10-Q 5 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 29, 2013	Oct. 31, 2013
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Document Period End Date	29-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Registrant Name	'PERKINELMER INC	'
Entity Central Index Key	'0000031791	'
Current Fiscal Year End Date	'--12-29	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	112,392,600
Entity Well-known Seasoned Issuer	'Yes	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'

Condensed_Consolidated_Income_

Condensed Consolidated Income Statements (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Sales Revenue, Goods, Net	$355,745	$349,067	$1,076,389	$1,070,504
Sales Revenue, Services, Net	168,532	160,537	496,563	471,780
Revenue	524,277	509,604	1,572,952	1,542,284
Cost of Goods Sold	192,256	182,179	569,143	555,078
Cost of Services	98,509	96,685	303,113	285,658
Cost of sales	290,765	278,864	872,256	840,736
Selling, general and administrative expenses	143,649	145,442	443,901	452,026
Research and development expenses	31,541	32,408	100,321	99,101
Restructuring and lease charges, net	1,126	9,672	23,713	21,034
Operating income from continuing operations	57,196	43,218	132,761	129,387
Interest and other expense, net	12,340	11,872	37,245	36,060
Income from continuing operations before income taxes	44,856	31,346	95,516	93,327
Provision for income taxes	4,557	2,357	-4,008	8,694
Net income from continuing operations	40,299	28,989	99,524	84,633
Gain (Loss) on disposition of discontinued operations before income taxes	-64	898	457	1,915
(Benefit from) provision for income taxes on discontinued operations and dispositions	37	293	-358	752
Net income (loss) from discontinued operations and dispositions	-101	605	815	1,163
Net income	$40,198	$29,594	$100,339	$85,796
Basic earnings (loss) per share:	'	'	'	'
Net income from continuing operations (per share)	$0.36	$0.25	$0.89	$0.75
Net income (loss) from discontinued operations and dispositions (per share)	$0	$0.01	$0.01	$0.01
Net Income (per share)	$0.36	$0.26	$0.89	$0.76
Diluted earnings (loss) per share:	'	'	'	'
Net income from continuing operations (per share)	$0.36	$0.25	$0.88	$0.74
Net income (loss) from discontinued operations and dispositions (per share)	$0	$0.01	$0.01	$0.01
Net income (per share)	$0.36	$0.26	$0.88	$0.75
Weighted average shares of common stock outstanding:	'	'	'	'
Basic (in shares)	111,827	113,860	112,285	113,491
Diluted (in shares)	113,115	114,998	113,516	114,565
Cash dividends per common share	$0.07	$0.07	$0.21	$0.21

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Net income	$40,198	$29,594	$100,339	$85,796
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	16,407	20,446	1,703	3,868
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	40	19	10	41
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax	299	299	897	897
Other Comprehensive Income (Loss), Net of Tax	16,746	20,764	2,610	4,806
Comprehensive Income, Net of Tax, Attributable to Parent	$56,944	$50,358	$102,949	$90,602

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$132,303	$171,444
Accounts receivable, net	428,531	457,011
Inventories, net	278,351	247,688
Other current assets	109,239	95,611
Total current assets	948,424	971,754
Property, plant and equipment, net:	'	'
At cost	508,411	513,479
Accumulated depreciation	-313,716	-302,963
Property, plant and equipment, net	194,695	210,516
Marketable securities and investments	1,220	1,149
Intangible assets, net	481,417	529,901
Goodwill	2,131,051	2,122,788
Other assets, net	94,719	65,654
Total assets	3,851,526	3,901,762
Current liabilities:	'	'
Short-term debt	2,622	1,772
Accounts payable	162,523	168,943
Accrued restructuring and integration costs	27,739	21,364
Accrued expenses	396,126	388,026
Current liabilities of discontinued operations	381	995
Total current liabilities	589,391	581,100
Long-term debt	933,292	938,824
Long-term liabilities	409,272	442,026
Total liabilities	1,931,955	1,961,950
Commitments and contingencies (see Note 18)	'	'
Stockholders' equity:	'	'
Preferred stock-$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock-$1 par value per share, authorized 300,000,000 shares; issued and outstanding	112,382	115,036
Capital in excess of par value	112,605	209,610
Retained earnings	1,625,381	1,548,573
Accumulated other comprehensive loss	69,203	66,593
Total stockholders' equity	1,919,571	1,939,812
Total liabilities and stockholders' equity	$3,851,526	$3,901,762

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 29, 2013	Dec. 30, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$1	$1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$1	$1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	112,382,000	115,036,000
Common stock, outstanding	112,382,000	115,036,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012
Operating activities:	'	'
Net income	$100,339	$85,796
Add: net income from discontinued operations and dispositions, net of income taxes	-815	-1,163
Net income from continuing operations	99,524	84,633
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:	'	'
Restructuring and lease charges, net	23,713	21,034
Depreciation and amortization	96,453	94,791
Stock-based compensation	11,423	15,352
Amortization of deferred debt issuance costs	2,598	2,655
Gains on disposition	-1,566	0
Amortization of acquired inventory revaluation	203	4,774
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:	'	'
Accounts receivable, net	26,839	15,088
Inventories, net	-31,782	-24,447
Accounts payable	-6,035	-18,611
Accrued expenses and other	-134,391	-79,725
Excess tax benefit from exercise of equity grants	0	-1,767
Net cash provided by operating activities of continuing operations	86,979	113,777
Net cash (used in) provided by operating activities of discontinued operations	-91	-1,131
Net cash provided by operating activities	86,888	112,646
Investing activities:	'	'
Capital expenditures	-31,564	-24,350
Proceeds from Life Insurance Policies	783	0
Proceeds from dispositions of property, plant and equipment, net	52,202	0
Changes in restricted cash balances	0	-670
Payments for acquisitions and investments, net of cash and cash equivalents acquired	-7,049	-6,750
Net cash used in investing activities of continuing operations	14,372	-30,430
Net cash provided by investing activities of discontinued operations	494	1,976
Net cash used in investing activities	14,866	-28,454
Financing activities:	'	'
Payments on debt	-429,000	-333,000
Proceeds from borrowings	419,000	291,000
Payments of debt issuance costs	0	-416
Payments for (Proceeds from) Hedge, Financing Activities	1,363	0
Payments on other credit facilities	5,530	-143
Payments for acquisition-related contingent consideration	0	-12,459
Excess tax benefit from exercise of equity grants	0	1,767
Proceeds from stock options exercised	15,292	22,944
Purchases of common stock	-127,186	-2,092
Dividends paid	-23,733	-23,875
Net cash (used in) provided by financing activities	-138,734	-56,274
Effect of exchange rate changes on cash and cash equivalents	-2,161	568
Net (decrease) increase in cash and cash equivalents	-39,141	28,486
Cash and cash equivalents at beginning of period	171,444	142,342
Cash and cash equivalents at end of period	$132,303	$170,828

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 29, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Accounting [Text Block]	'
	Basis of Presentation
	The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), without audit, in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 30, 2012, filed with the SEC (the “2012 Form 10-K”). The balance sheet amounts at December 30, 2012 in this report were derived from the Company’s audited 2012 consolidated financial statements included in the 2012 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended September 29, 2013 and September 30, 2012, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from September 29, 2013 through the date of the issuance of these condensed consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these condensed consolidated financial statements or would require additional disclosure.
	Recently Adopted Accounting Pronouncements: During the first quarter of fiscal year 2013 the Company adopted new guidance on additional disclosure requirements of other comprehensive income. This new guidance requires the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the three and nine months ended September 29, 2013. See Note 11 for additional details.
	Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, the Company believes that such recently issued pronouncements will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
New Accounting Pronouncement or Change in Accounting Principle, Description	'Recently Adopted Accounting Pronouncements: During the first quarter of fiscal year 2013 the Company adopted new guidance on additional disclosure requirements of other comprehensive income. This new guidance requires the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the three and nine months ended SeptemberB 29, 2013. See Note 11 for additional details.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	'
	Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, the Company believes that such recently issued pronouncements will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.

Business_Combinations

Business Combinations	9 Months Ended
	Sep. 29, 2013
Business Combinations [Abstract]	'
Business Combinations	'
	Business Combinations
	Acquisition of Haoyuan Biotech Co., Ltd. In November 2012, the Company acquired all outstanding stock of Shanghai Haoyuan Biotech Co., Ltd. ("Haoyuan"). Haoyuan is a provider of nucleic acid-based blood screening solutions for the blood banking and clinical diagnostics markets. The Company expects this acquisition to extend the Company's capabilities into nucleic acid blood screening, as well as deepen its position in the growing molecular clinical diagnostics market in China. The Company paid the shareholders of Haoyuan $38.0 million in cash for the stock of Haoyuan. The Company recorded a receivable of $2.7 million from the shareholders of Haoyuan as a reduction of purchase price for the settlement of certain contingencies. As of the closing date, the Company potentially had to pay the shareholders additional contingent consideration of up to $30.0 million, which at closing had an estimated fair value of $1.9 million. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for this acquisition within the results of the Company’s Human Health segment from the acquisition date.
	The total purchase price has been preliminarily allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Haoyuan
		(Preliminary)
		(In thousands)
	Fair value of business combination:
	Cash payments	$	38,000
	Contingent consideration	1,900
	Working capital and other adjustments	(2,729		)
	Less cash acquired	(175		)
	Total	$	36,996
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	2,389
	Property, plant and equipment	2,906
	Identifiable intangible assets:
	Core technology	17,700
	Trade names	400
	IPR&D	300
	Goodwill	19,682
	Deferred taxes	(2,656		)
	Liabilities assumed	(3,725		)
	Total	$	36,996
	The weighted average amortization periods of identifiable definite-lived intangible assets for core technology and trade names were 8.0 years.
	As of September 29, 2013, the purchase price allocation for the Haoyuan acquisition was preliminary. The preliminary allocation of the purchase price for the Haoyuan acquisition was based upon an initial valuation and the Company's estimates and assumptions underlying the initial valuation are subject to change within the measurement period (up to one year from the acquisition date). The primary areas of the preliminary purchase price allocation that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition date during the measurement period. During the measurement period, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date. Adjustments to the preliminary allocation of the purchase price during the measurement period require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocation of the purchase price made during the measurement period would be as if the adjustments had been completed on the acquisition date. The effects of any such adjustments, if material, will cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement period are included in current period earnings.
	Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $37.0 million as of September 29, 2013. As of September 29, 2013, the Company has recorded contingent consideration obligations relating to these acquisitions, with an estimated fair value of $2.9 million. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional consideration which would be expensed.
	Total transaction costs related to acquisition activities for the three and nine months ended September 29, 2013 were zero and $0.1 million, respectively. Total transaction costs related to acquisition activities for the three and nine months ended September 30, 2012 were $0.3 million and $0.6 million, respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 29, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
	Discontinued Operations
	As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within the assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of September 29, 2013 and December 30, 2012.
	The Company recorded the following gains and losses, which have been reported as a (loss) gain on disposition of discontinued operations:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Gain on disposition of Photoflash business	$	—		$	974		$	493		$	1,966
	Loss on disposition of other discontinued operations	(64		)	(76		)	(36		)	(51		)
	(Loss) gain on disposition of discontinued operations before income taxes	$	(64	)	$	898		$	457		$	1,915
	In June 2010, the Company sold its Photoflash business, which was included in the Company's Environmental Health segment, for $13.5 million, including an adjustment for net working capital, plus potential additional contingent consideration. During the nine months ended September 29, 2013, the Company recognized a pre-tax gain of $0.5 million for contingent consideration related to this sale. During the nine months ended September 30, 2012, the Company recognized a pre-tax gain of $2.0 million for contingent consideration related to this sale. These gains were recognized as a gain on disposition of discontinued operations.
	During the first nine months of both fiscal years 2013 and 2012, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized pre-tax losses in the first nine months of both fiscal year 2013 and fiscal year 2012. These losses were recognized as a loss on disposition of discontinued operations.
	The Company recorded a tax provision of $0.04 million and a tax benefit of $0.4 million on disposition of discontinued operations for the three and nine months ended September 29, 2013, respectively. The Company recorded tax provisions of $0.3 million and $0.8 million on disposition of discontinued operations for the three and nine months ended September 30, 2012, respectively.

Restructuring_and_Lease_Charge

Restructuring and Lease Charges, Net	9 Months Ended
	Sep. 29, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring and Lease Charges, Net	'
	Restructuring and Contract Termination Charges, Net
	The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with the Company’s growth strategy and the integration of its business units. The current portion of restructuring and contract termination charges, is recorded in accrued restructuring and contract termination charges, and the long-term portion of restructuring and contract termination charges, is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
	A description of the restructuring plans and the activity recorded for the nine months ended September 29, 2013 is listed below. Details of the plans initiated in previous years, particularly those listed under “Previous Restructuring and Integration Plans,” are discussed more fully in Note 4 to the audited consolidated financial statements in the 2012 Form 10-K.
	The restructuring plan for the third quarter of fiscal year 2013 was principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation. The restructuring plan for the second quarter of fiscal year 2013 was principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources and production resources as a result of previous acquisitions. The restructuring plan for the first quarter of fiscal year 2013 was principally intended to focus resources on higher growth end markets. The restructuring plan for the fourth quarter of fiscal year 2012 was principally intended to shift resources to higher growth geographic regions and end markets. The restructuring plan for the third quarter of fiscal year 2012 was principally intended to shift certain of the Company's operations into a newly established shared service center. The restructuring plans for the first and second quarters of fiscal year 2012 were principally intended to realign operations, research and development resources and production resources as a result of previous acquisitions.
	A description of the restructuring plans and the activity recorded are as follows:
	Q3 2013 Restructuring Plan
	During the third quarter of fiscal year 2013, the Company’s management approved a plan to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q3 2013 Plan”). As a result of the Q3 2013 Plan, the Company recognized a $0.5 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q3 2013 Plan, the Company will reduce headcount by 30 employees. All employees were notified of termination under the Q3 2013 Plan by September 29, 2013.
	The following table summarizes the Q3 2013 Plan activity for the nine months ended September 29, 2013:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Provision	$	394		$	138		$	532
	Amounts paid and foreign currency translation	—			(26		)	(26		)
	Balance at September 29, 2013	$	394		$	112		$	506
	The Company anticipates that the remaining severance payments of $0.4 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2014. The Company also anticipates that the remaining payments of $0.1 million for the closure of the excess facility space will be paid through fiscal year 2013, in accordance with the terms of the applicable lease.
	Q2 2013 Restructuring Plan
	During the second quarter of fiscal year 2013, the Company’s management approved a plan to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2013 Plan”). As a result of the Q2 2013 Plan, and during the nine months ended September 29, 2013, the Company recognized a $10.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $8.8 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. The Company expects to recognize an additional $0.3 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits. This expense will be recognized ratably over the required service period. As part of the Q2 2013 Plan, the Company will reduce headcount by 265 employees. All employees were notified of termination under the Q2 2013 Plan by June 30, 2013.
	The following table summarizes the Q2 2013 Plan activity for the nine months ended September 29, 2013:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Provision	$	18,476		$	572		$	19,048
	Amounts paid and foreign currency translation	(3,824		)	(519		)	(4,343		)
	Balance at September 29, 2013	$	14,652		$	53		$	14,705
	The Company anticipates that the remaining severance payments of $14.7 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. The Company also anticipates that the remaining payments of $0.1 million for the closure of the facility space will be paid through fiscal year 2013, in accordance with the terms of the applicable leases.
	Q1 2013 Restructuring Plan
	During the first quarter of fiscal year 2013, the Company’s management approved a plan to focus resources on higher growth end markets (the “Q1 2013 Plan”). As a result of the Q1 2013 Plan, the Company recognized a $2.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q1 2013 Plan, the Company reduced headcount by 62 employees. All employees were notified of termination under the Q1 2013 Plan by March 31, 2013.
	The following table summarizes the Q1 2013 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Provision	$	2,585
	Amounts paid and foreign currency translation	(2,371		)
	Balance at September 29, 2013	$	214
	The Company anticipates that the remaining severance payments of $0.2 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014.
	Q4 2012 Restructuring Plan
	During the fourth quarter of fiscal year 2012, the Company’s management approved a plan to shift resources to higher growth geographic regions and end markets (the “Q4 2012 Plan”). As a result of the Q4 2012 Plan, and during fiscal year 2012, the Company recognized a $0.6 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $2.4 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q4 2012 Plan, the Company reduced headcount by 54 employees. All employees were notified of termination under the Q4 2012 Plan by December 30, 2012.
	The following table summarizes the Q4 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	2,682
	Amounts paid and foreign currency translation	(2,016		)
	Balance at September 29, 2013	$	666
	The Company anticipates that the remaining severance payments of $0.7 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2014.
	Q3 2012 Restructuring Plan
	During the third quarter of fiscal year 2012, the Company’s management approved a plan to shift certain of the Company's operations into a newly established shared service center (the “Q3 2012 Plan”). As a result of the Q3 2012 Plan, and during fiscal year 2012, the Company recognized $3.9 million pre-tax restructuring charges in each of the Human Health and Environmental Health segments related to a workforce reduction from reorganization activities. During the nine months ended September 29, 2013, the Company recorded a pre-tax restructuring reversal of $0.3 million in each of the Human Health and Environmental Health segments due to lower than expected costs associated with remaining severance payments. As part of the Q3 2012 Plan, the Company reduced headcount by 66 employees. All employees were notified of termination under the Q3 2012 Plan by September 30, 2012.
	The following table summarizes the Q3 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	7,553
	Change in estimates	(546		)
	Amounts paid and foreign currency translation	(2,859		)
	Balance at September 29, 2013	$	4,148
	The Company anticipates that the remaining severance payments of $4.1 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014.
	Q2 2012 Restructuring Plan
	During the second quarter of fiscal year 2012, the Company’s management approved a plan to realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2012 Plan”). As a result of the Q2 2012 Plan, and during fiscal year 2012, the Company recognized a $7.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. During the nine months ended September 29, 2013, the Company recognized a $2.1 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and a $0.1 million pre-tax restructuring reversal in the Environmental Health segment due to lower than expected costs associated with remaining severance payments. The Company expects to recognize an additional $0.2 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits. This expense will be recognized ratably over the required service period. As part of the Q2 2012 Plan, the Company will reduce headcount by 203 employees. All employees were notified of termination under the Q2 2012 Plan by July 1, 2012.
	The following table summarizes the Q2 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	4,586
	Provision	2,052
	Amounts paid and foreign currency translation	(3,975		)
Balance at September 29, 2013	$	2,663
The Company anticipates that the remaining severance payments of $2.7 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2013.
Q1 2012 Restructuring Plan
During the first quarter of fiscal year 2012, the Company’s management approved a plan to realign operations and production resources as a result of previous acquisitions (the “Q1 2012 Plan”). As a result of the Q1 2012 Plan, and during fiscal year 2012, the Company recognized a $5.4 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $1.0 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. The Company expects to recognize no additional incremental restructuring expense in future periods as all services were provided for one-time termination benefits in which the employee was required to render service until termination in order to receive the benefits. As part of the Q1 2012 Plan, the Company reduced headcount by 112 employees. All employees were notified of termination and the Company completed all actions related to the closure of excess facility space under the Q1 2012 Plan by April 1, 2012.
The following table summarizes the Q1 2012 Plan activity for the nine months ended September 29, 2013:
	Severance
	(In thousands)
Balance at December 30, 2012	$	1,281
Provision	30
Amounts paid and foreign currency translation	(594		)
Balance at September 29, 2013	$	717
The Company anticipates that the remaining severance payments of $0.7 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2013. The closure of the excess facility space will not require any additional payments.
Previous Restructuring and Integration Plans
The principal actions of the restructuring and integration plans from fiscal years 2001 through 2011 were workforce reductions related to the integration of the Company’s businesses in order to reduce costs and achieve operational efficiencies as well as workforce reductions in both the Human Health and Environmental Health segments by shifting resources into geographic regions and end markets that are more consistent with the Company’s growth strategy. During the nine months ended September 29, 2013, the Company paid $1.9 million related to these plans and recorded a reversal of $0.3 million primarily related to lower than expected costs associated with workforce reductions within the Environmental Health segment. As of September 29, 2013, the Company had $8.9 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both the Human Health and Environmental Health segments. The Company expects to make payments for these leases, the terms of which vary in length, through fiscal year 2022.
Contract Termination Charges
The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded an additional pre-tax charge of $0.3 million and made payments for these obligations of $0.9 million in the first nine months of fiscal year 2013. The remaining balance of these accruals as of September 29, 2013 was $0.1 million.

Interest_and_Other_Expense_Inc

Interest and Other Expense (Income), Net	9 Months Ended
	Sep. 29, 2013
Other Income and Expenses [Abstract]	'
Interest and Other Expense (Income), Net	'
	Interest and Other Expense, Net
	Interest and other expense, net, consisted of the following:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Interest income	$	(119	)	$	(74	)	$	(288	)	$	(434	)
	Interest expense	11,704			11,360			35,310			34,136
	Other expense, net	755			586			2,223			2,358
	Total interest and other expense, net	$	12,340		$	11,872		$	37,245		$	36,060

Inventories_Net

Inventories, Net	9 Months Ended
	Sep. 29, 2013
Inventory Disclosure [Abstract]	'
Inventories, Net	'
	Inventories, Net
	Inventories as of September 29, 2013 and December 30, 2012 consisted of the following:
		September 29,		December 30,
		2013		2012
		(In thousands)
	Raw materials	$	101,562	$	74,924
	Work in progress	15,502		12,768
	Finished goods	161,287		159,996
	Total inventories, net	$	278,351	$	247,688

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 29, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.
	At September 29, 2013, the Company had gross tax effected unrecognized tax benefits of $48.5 million, of which $42.1 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations.
	The Company believes that it is reasonably possible that $11.5 million of its uncertain tax positions at September 29, 2013, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2006 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
	During the first nine months of fiscal year 2013, the Company recorded net discrete income tax benefits of $15.6 million primarily for reversals of uncertain tax position reserves and resolution of other tax matters, which included $9.4 million of reversals as a result of lapses in statutes of limitations during the first quarter of fiscal year 2013.
	As a result of the Caliper acquisition, the Company concluded in fiscal year 2011 that certain foreign operations did not require the same level of capital as previously expected, and therefore the Company planned to repatriate approximately $350.0 million of previously unremitted earnings and has provided for the estimated taxes on the repatriation of those earnings. As a result of the planned repatriation, the Company recorded an increase to the Company’s tax provision of $79.7 million in continuing operations in fiscal year 2011. The Company expects to utilize tax attributes, primarily those acquired in the Caliper acquisition, to minimize the cash taxes paid on the repatriation. As of September 29, 2013, the Company had completed the repatriation of the $350.0 million of foreign earnings and increased its estimated tax liability associated with the repatriation by approximately $2.4 million, which was recorded as tax expense during the third quarter of fiscal year 2013. The Company continues to maintain its indefinite reinvestment assertion with regards to the remaining unremitted earnings of its foreign subsidiaries, and therefore does not accrue U.S. tax for the repatriation of its remaining unremitted foreign earnings.

Debt

Debt	9 Months Ended
	Sep. 29, 2013
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	Senior Unsecured Revolving Credit Facility. The Company's senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of December 16, 2016. As of September 29, 2013, undrawn letters of credit in the aggregate amount of $12.0 million were treated as issued and outstanding under the senior unsecured revolving credit facility. As of September 29, 2013, the Company had $440.0 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by Bank of America, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. The Eurocurrency margin as of September 29, 2013 was 130 basis points. The weighted average Eurocurrency interest rate as of September 29, 2013 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.48%, which is the interest applicable to borrowings outstanding under the Eurocurrency rate as of September 29, 2013. At September 29, 2013 and December 30, 2012, the Company had $248.0 million and $258.0 million, respectively, of borrowings in U.S. Dollars outstanding under the senior unsecured revolving credit facility with interest based primarily on the above described Eurocurrency rate. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default customary for financings of this type and similar to those contained in the Company's credit agreement for its previous facility. The financial covenants in the Company's senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade.
	6% Senior Unsecured Notes due 2015. On May 30, 2008, the Company issued $150.0 million aggregate principal amount of senior unsecured notes due 2015 (the “2015 Notes”) in a private placement and received $150.0 million of proceeds from the issuance. The 2015 Notes mature in May 2015 and bear interest at an annual rate of 6%. Interest on the 2015 Notes is payable semi-annually on May 30th and November 30th each year. The Company may redeem some or all of the 2015 Notes at any time, at its option, at a make-whole redemption price plus accrued and unpaid interest. The indenture governing the 2015 Notes includes a financial covenant of a debt-to-capital ratio, and a contingent covenant, a multiple of total debt to earnings ratio, applicable only if the Company's credit rating is downgraded below investment grade.
	5% Senior Unsecured Notes due 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due 2021 (the “2021 Notes”) in a registered public offering and received approximately $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of September 29, 2013, the 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes ) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest.
	Financing Lease Obligations. In September 2012, the Company entered into agreements with the lessors of buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, which resulted in the Company being considered the owner of the buildings during the construction period. At the end of the construction period, the Company will not be reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases will qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million of the expected $15.0 million in additional construction costs to complete the renovations to the buildings, which were funded by the lessors. At September 29, 2013, the Company had $40.5 million recorded for these financing lease obligations, of which $2.6 million was recorded as short-term debt and $37.9 million was recorded as long-term debt. At December 30, 2012, the Company had $34.6 million recorded for these financing lease obligations, of which $1.7 million was recorded as short-term debt and $32.9 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 29, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:
		Three Months Ended		Nine Months Ended
		September 29,	September 30,	September 29,	September 30,
		2013	2012	2013	2012
		(In thousands)
	Number of common shares—basic	111,827	113,860	112,285	113,491
	Effect of dilutive securities:
	Stock options	997	830	987	827
	Restricted stock awards	291	308	244	247
	Number of common shares—diluted	113,115	114,998	113,516	114,565
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	465	1,381	493	1,448
	Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry_Segment_Information

Industry Segment Information	9 Months Ended
	Sep. 29, 2013
Segment Reporting [Abstract]	'
Industry Segment Information	'
	Industry Segment Information
	The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2012 Form 10-K.
	The Company realigned its organization at the beginning of fiscal year 2013. The Company's field service for products previously sold by its former Bio-discovery business, as well as its Informatics business, was moved from the Environmental Health segment into the Human Health segment. The results reported for the three and nine months ended September 29, 2013 reflect this new alignment of the Company's operating segments. Financial information in this report relating to the three and nine months ended September 30, 2012 has been retrospectively adjusted to reflect the changes to the operating segments. The principal products and services of these two operating segments are:
	•	Human Health.    Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.
	•	Environmental Health.    Provides technologies and applications to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
	The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the expense related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
	Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Human Health
	Product revenue	$	227,167		$	225,029		$	682,164		$	671,576
	Service revenue	65,217			62,224			191,492			184,208
	Total revenue	292,384			287,253			873,656			855,784
	Operating income from continuing operations	43,901			34,398			98,997			82,962
	Environmental Health
	Product revenue	128,578			124,038			394,225			398,928
	Service revenue	103,315			98,313			305,071			287,572
	Total revenue	231,893			222,351			699,296			686,500
	Operating income from continuing operations	21,896			18,475			61,922			77,948
	Corporate
	Operating loss from continuing operations(1)	(8,601		)	(9,655		)	(28,158		)	(31,523		)
	Continuing Operations
	Product revenue	$	355,745		$	349,067		$	1,076,389		$	1,070,504
	Service revenue	168,532			160,537			496,563			471,780
	Total revenue	524,277			509,604			1,572,952			1,542,284
	Operating income from continuing operations	57,196			43,218			132,761			129,387
	Interest and other expense, net (see Note 5)	12,340			11,872			37,245			36,060
	Income from continuing operations before income taxes	$	44,856		$	31,346		$	95,516		$	93,327
	____________________________
	(1)	The expenses related to the mark-to-market adjustment on postretirement benefit plans have been included in the Corporate operating loss from continuing operations, and together constituted a pre-tax gain of $0.05 million and a pre-tax loss of $1.2 million for the nine months ended September 29, 2013 and September 30, 2012, respectively. There were no expenses related to the mark-to-market adjustment on postretirement benefit plans for either the three months ended September 29, 2013 or September 30, 2012.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 29, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Comprehensive Income:
	The components of accumulated other comprehensive income consisted of the following:
		September 29,			December 30,
		2013			2012
		(In thousands)
	Foreign currency translation adjustments	$	69,230		$	67,527
	Unrecognized prior service costs, net of income taxes	2,087			2,087
	Unrealized and realized losses on derivatives, net of income taxes	(1,995		)	(2,892		)
	Unrealized net losses on securities, net of income taxes	(119		)	(129		)
	Accumulated other comprehensive income	$	69,203		$	66,593
	During the nine months ended September 29, 2013, pre-tax losses of $1.5 million were reclassified from accumulated other comprehensive income into interest and other expense, net related to previously settled cash flow hedges. The Company recognized a tax provision of $0.6 million related to these amounts reclassified out of accumulated other comprehensive income for the nine months ended September 29, 2013.
	Stock Repurchase Program:
	On October 24, 2012, the Board authorized the Company to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on October 24, 2014 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During the first nine months of fiscal year 2013, the Company repurchased 3.6 million shares of common stock in the open market at an aggregate cost of $123.0 million, including commissions, under the Repurchase Program. As of September 29, 2013, 2.4 million shares of the Company’s common stock remained available for repurchase from the 6.0 million shares authorized by the Board under the Repurchase Program.
	The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans. During the first nine months of fiscal year 2013, the Company repurchased 122,015 shares of common stock for this purpose at an aggregate cost of $4.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
	Dividends:
	The Board declared a regular quarterly cash dividend of $0.07 per share for each of the first three quarters of fiscal year 2013 and for each quarter of fiscal year 2012. At September 29, 2013, the Company had accrued $7.9 million for dividends declared on July 26, 2013 for the third quarter of fiscal year 2013, payable in November 2013. On October 24, 2013, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year 2013 that will be payable in February 2014. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock_Plans

Stock Plans	9 Months Ended
	Sep. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Plans	'
	Stock Plans
	In addition to the Company's Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company’s common stock, as well as shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued, are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs.
	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and nine months ended September 29, 2013 and September 30, 2012:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Cost of product and service revenue	$	337		$	327		$	958		$	906
	Research and development expenses	203			186			629			547
	Selling, general and administrative expenses	3,241			4,588			9,836			13,899
	Total stock-based compensation expense	$	3,781		$	5,101		$	11,423		$	15,352
	The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.2 million and $3.6 million for the three and nine months ended September 29, 2013, respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.6 million and $5.0 million for the three and nine months ended September 30, 2012, respectively. Stock-based compensation costs capitalized as part of inventory were $0.3 million as of both September 29, 2013 and September 30, 2012. The excess tax benefit recognized from stock awards, classified as a financing cash activity, was zero and $1.8 million for the nine months ended September 29, 2013 and September 30, 2012, respectively.
	Stock Options: The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
		Three and Nine Months Ended
		September 29,		September 30,
		2013		2012
	Risk-free interest rate	0.9	%	0.6	%
	Expected dividend yield	0.8	%	1.2	%
	Expected lives	5 years		4 years
	Expected stock volatility	38.5	%	38.7	%
	The following table summarizes stock option activity for the nine months ended September 29, 2013:
		Number		Weighted-			Weighted-Average		Total
		of		Average			Remaining		Intrinsic
		Shares		Price			Contractual Term		Value
		(In thousands)					(In years)		(In millions)
	Outstanding at December 30, 2012	4,266		$	21.64
	Granted	518		33.62
	Exercised	(721	)	21.2
	Canceled	(7	)	22.63
	Forfeited	(325	)	22.82
	Outstanding at September 29, 2013	3,731		$	23.29		3.6		$	46.9
	Exercisable at September 29, 2013	2,590		$	20.82		2.7		$	38.9
	Vested and expected to vest in the future	3,683		$	22.93		3.6		$	46.5
	There were no options granted during the three months ended September 29, 2013. The weighted-average per-share grant-date fair value of options granted for the nine months ended September 29, 2013 was $10.82. The weighted-average per-share grant-date fair value of options granted for the three and nine months ended September 30, 2012 was $7.71 and $7.36, respectively. The total intrinsic value of options exercised for the three and nine months ended September 29, 2013 was $6.2 million and $10.3 million, respectively. The total intrinsic value of options exercised for the three and nine months ended September 30, 2012 was $3.9 million and $9.1 million, respectively. Cash received from option exercises for the nine months ended September 29, 2013 and September 30, 2012 was $15.3 million and $22.9 million, respectively.
	The total compensation expense recognized related to the Company’s outstanding options was $1.1 million and $3.2 million for the three and nine months ended September 29, 2013, respectively, and $1.2 million and $3.7 million for the three and nine months ended September 30, 2012, respectively.
	There was $6.8 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of September 29, 2013. This cost is expected to be recognized over a weighted-average period of 1.9 years and will be adjusted for any future changes in estimated forfeitures.
	Restricted Stock Awards: The following table summarizes restricted stock award activity for the nine months ended September 29, 2013:
		Number of		Weighted-
		Shares		Average
				Grant-
				Date Fair
				Value
		(In thousands)
	Nonvested at December 30, 2012	781		$	24.71
	Granted	277		33.74
	Vested	(327	)	23.23
	Forfeited	(70	)	28.67
	Nonvested at September 29, 2013	661		$	28.8
	The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and nine months ended September 29, 2013 was $36.11 and $33.74, respectively. The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and nine months ended September 30, 2012 was $27.06 and $25.85, respectively. The fair value of restricted stock awards vested for the three and nine months ended September 29, 2013 was $0.4 million and $7.6 million, respectively. The fair value of restricted stock awards vested for the three and nine months ended September 30, 2012 was $0.1 million and $4.2 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $1.7 million and $5.6 million for the three and nine months ended September 29, 2013, respectively, and $1.9 million and $6.1 million for the three and nine months ended September 30, 2012, respectively.
	As of September 29, 2013, there was $10.8 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.4 years.
	Performance Units: The Company granted 98,056 and 122,675 performance units during the nine months ended September 29, 2013 and September 30, 2012, respectively, as part of the Company’s executive incentive program. The weighted-average per-share grant-date fair value of performance units granted during the nine months ended September 29, 2013 and September 30, 2012 was $34.06 and $26.18, respectively. The total compensation expense recognized related to these performance units was $1.0 million and $1.9 million for the three and nine months ended September 29, 2013, respectively, and $1.9 million and $4.9 million for the three and nine months ended September 30, 2012, respectively. As of September 29, 2013, there were 282,044 performance units outstanding and subject to forfeiture, with a corresponding liability of $5.4 million recorded in accrued expenses and other current liabilities.
	Stock Awards: The Company generally grants stock awards only to non-employee members of the Board. The Company granted 3,263 shares and 3,580 shares to each non-employee member of the Board during the nine months ended September 29, 2013 and September 30, 2012, respectively. The Company also granted 955 shares to a new non-employee member of the Board during the nine months ended September 30, 2012. The weighted-average per-share grant-date fair value of the stock awards granted during the nine months ended September 29, 2013 and September 30, 2012 was $30.65 and $27.87, respectively. No compensation expense was recognized related to these stock awards in each of the three months ended September 29, 2013 and September 30, 2012. The total compensation expense recognized related to these stock awards was $0.7 million for each of the nine months ended September 29, 2013 and September 30, 2012.
	Employee Stock Purchase Plan: During the nine months ended September 29, 2013, the Company issued 89,521 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $30.51 per share. At September 29, 2013, an aggregate of 1.1 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 29, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets, Net	'
	Goodwill and Intangible Assets, Net
	The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.
	As discussed in Note 10, the Company realigned its organization at the beginning of fiscal year 2013, which resulted in a change in the composition of the Company's reporting units and reportable segments. The Company's field service for products previously sold by its former Bio-discovery business, as well as its Informatics business, was moved from the Environmental Health segment into the Human Health segment. The results reported for this quarter reflect this new alignment of the Company's operating segments. Financial information in this report relating to fiscal year 2012 has been retrospectively adjusted to reflect the changes to the operating segments. As a result of the realignment, the Company reallocated goodwill from the Environmental Health segment to the Human Health segment based on the relative fair value, determined using the income approach, of the businesses within the historical Environmental Health segment. The change resulted in $215.7 million of goodwill being allocated from the Environmental Health segment to the Human Health segment as of December 30, 2012.
	The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2013, its annual impairment date for fiscal year 2013, and concluded based on the first step of the process that there was no goodwill impairment. The fair values of each of the Company's reporting units were substantially in excess of their carrying values.
	The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rate and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The long-term terminal growth rates for the Company’s reporting units ranged from 4.5% to 6.0% for the fiscal year 2013 impairment analysis. The range for the discount rates for the reporting units was 10.5% to 12.0%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.
	The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company currently evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2013, and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first nine months of fiscal year 2013.
	The changes in the carrying amount of goodwill for the period ended September 29, 2013 from December 30, 2012 were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 30, 2012	$	1,632,487		$	490,301		$	2,122,788
	Foreign currency translation	7,069			556			7,625
	Acquisitions and other	—			638			638
	Balance at September 29, 2013	$	1,639,556		$	491,495		$	2,131,051
	Identifiable intangible asset balances at September 29, 2013 and December 30, 2012 by category were as follows:
		September 29,			December 30,
		2013			2012
		(In thousands)
	Patents	$	101,831		$	107,969
	Less: Accumulated amortization	(85,789		)	(89,954		)
	Net patents	16,042			18,015
	Trade names and trademarks	36,430			37,694
	Less: Accumulated amortization	(15,784		)	(13,886		)
	Net trade names and trademarks	20,646			23,808
	Licenses	79,208			80,607
	Less: Accumulated amortization	(50,509		)	(47,368		)
	Net licenses	28,699			33,239
	Core technology	408,342			407,545
	Less: Accumulated amortization	(271,440		)	(248,510		)
	Net core technology	136,902			159,035
	Customer relationships	325,533			327,637
	Less: Accumulated amortization	(122,499		)	(108,384		)
	Net customer relationships	203,034			219,253
	IPR&D	7,510			7,463
	Less: Accumulated amortization	(2,000		)	(1,496		)
	Net IPR&D	5,510			5,967
	Net amortizable intangible assets	410,833			459,317
	Non-amortizing intangible assets:
	Trade names and trademarks	70,584			70,584
	Total	$	481,417		$	529,901
	Total amortization expense related to definite-lived intangible assets was $23.1 million and $67.9 million for the three and nine months ended September 29, 2013, respectively, and $22.0 million and $68.7 million for the three and nine months September 30, 2012, respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $21.9 million for the remainder of fiscal year 2013, $81.1 million for fiscal year 2014, $67.7 million for fiscal year 2015, $58.8 million for fiscal year 2016, and $47.7 million for fiscal year 2017.
	The Company entered into a strategic agreement in fiscal year 2012 under which it acquired certain intangible assets and received a license to certain core technology for an analytics and data discovery platform, as well as the exclusive right to distribute the platform in certain scientific research and development markets. During fiscal year 2012, the Company paid $6.8 million for net intangible assets and $25.0 million for prepaid royalties. During the third quarter of fiscal year 2013, the Company extended the existing agreement for an additional year. In addition, the Company entered into a new agreement to expand the distribution rights to the clinical and other related markets and acquired additional intangible assets. During the first nine months of fiscal year 2013, the Company paid $7.0 million for net intangible assets and $27.8 million for prepaid royalties, and expects to pay an additional $13.0 million in prepaid royalties within the next twelve months. The Company expects to expense royalties as revenue is recognized. These intangible assets are being amortized over their estimated useful lives. The Company has reported the amortization of these intangible assets within the results of the Company's Human Health segment from the execution date.

Warranty_Reserves

Warranty Reserves	9 Months Ended
	Sep. 29, 2013
Product Warranties Disclosures [Abstract]	'
Warranty Reserves	'
	Warranty Reserves
	The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets.
	Warranty reserve activity for the three and nine months ended September 29, 2013 and September 30, 2012 is summarized below:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Balance beginning of period	$	10,451		$	10,625		$	11,003		$	10,412
	Provision charged to income	4,160			4,063			12,673			12,960
	Payments	(4,113		)	(4,304		)	(12,781		)	(13,344		)
	Adjustments to previously provided warranties, net	268			221			(54		)	708
	Foreign currency translation and acquisitions	122			154			47			23
	Balance end of period	$	10,888		$	10,759		$	10,888		$	10,759

Employee_Benefit_Plans

Employee Benefit Plans	9 Months Ended
	Sep. 29, 2013
Compensation and Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	Employee Postretirement Benefit Plans
	The following table summarizes the components of net periodic benefit (credit) cost for the Company’s various defined benefit employee pension and postretirement plans for the three and nine months ended September 29, 2013 and September 30, 2012:
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Three Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Service cost	$	916		$	977		$	28		$	28
	Interest cost	5,312			5,774			36			37
	Expected return on plan assets	(6,261		)	(5,140		)	(241		)	(219		)
	Amortization of prior service costs	(67		)	(60		)	—			—
	Net periodic benefit (credit) cost	$	(100	)	$	1,551		$	(177	)	$	(154	)
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Service cost	$	2,757		$	2,934		$	85		$	85
	Interest cost	15,925			17,381			107			111
	Expected return on plan assets	(18,778		)	(15,422		)	(723		)	(657		)
	Amortization of prior service	(201		)	(180		)	—			—
	Net periodic benefit (credit) cost	$	(297	)	$	4,713		$	(531	)	$	(461	)
	During the first nine months of fiscal year 2013, the Company made contributions of $37.0 million for the 2012 plan year to its defined benefit pension plan in the United States. The Company contributed $17.9 million, in the aggregate, to plans outside of the United States during the first nine months of fiscal year 2013, including an additional contribution of $10.0 million to its defined benefit pension plan in the United Kingdom.

Derivatives_And_Hedging_Activi

Derivatives And Hedging Activities	9 Months Ended
	Sep. 29, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Hedging Activities	'
	Derivatives and Hedging Activities
	The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures.
	In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. Unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying condensed consolidated balance sheets. Deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs and impacts earnings.
	Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as fair value hedges, with U.S. equivalent notional amounts totaling $110.0 million, $64.3 million and $66.6 million at September 29, 2013, December 30, 2012 and September 30, 2012, respectively, and the approximate fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during both fiscal years 2013 and 2012.
	In December 2012, the Company entered into forward foreign exchange contracts with settlement dates in fiscal year 2013 and combined Euro denominated notional amounts of €50.0 million, designated as cash flow hedges. During the first two quarters of fiscal year 2013 the Company settled these Euro denominated forward foreign exchange contracts. The derivative gains were amortized into interest and other expense, net, when the hedged exposures affected interest and other expense, net. Such amounts were not material for the nine months ended September 29, 2013.
	In May 2008, the Company settled forward interest rate contracts with notional amounts totaling $150.0 million upon the issuance of its 2015 Notes, and recognized $8.4 million, net of taxes of $5.4 million, of accumulated derivative losses in other comprehensive income. As of September 29, 2013, the balance remaining in accumulated other comprehensive income related to the effective cash flow hedges was a loss of $2.0 million, net of taxes of $1.3 million. The Company amortized a pre-tax loss of $1.5 million into interest and other expense, net during each of the nine months ended September 29, 2013 and September 30, 2012, respectively. The derivative losses are being amortized into interest and other expense, net when the hedged exposure affects interest and other expense, net.
	Assuming current market conditions continue, a $2.0 million pre-tax loss is expected to be reclassified from accumulated other comprehensive income into interest and other expense, net within the next 12 months.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 29, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of September 29, 2013.
	The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the nine months ended September 29, 2013. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
	Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of September 29, 2013 and December 30, 2012 classified in one of the three classifications described above:
		Fair Value Measurements at September 29, 2013 Using:
		Total Carrying Value at September 29, 2013			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,220		$	1,220		$	—		$	—
	Foreign exchange derivative assets	246			—			246			—
	Foreign exchange derivative liabilities	(207		)	—			(207		)	—
	Contingent consideration	(2,858		)	—			—			(2,858		)
		Fair Value Measurements at December 30, 2012 Using:
		Total Carrying Value at December 30, 2012			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,149		$	1,149		$	—		$	—
	Foreign exchange derivative assets	274			—			274			—
	Foreign exchange derivative liabilities	(294		)	—			(294		)	—
	Contingent consideration	(3,017		)	—			—			(3,017		)
	Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
	Marketable securities:    Include equity and fixed-income securities measured at fair value using the quoted market prices at the reporting date.
	Foreign exchange derivative assets and liabilities:    Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date.
	Contingent consideration:    The Company has classified its net liabilities for contingent consideration relating to its acquisitions of ID Biological Systems, Inc., Dexela Limited, Haoyuan and Tetra Teknolojik Sistemler Limited Sirketi within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. A description of the significant acquisitions is included within Note 2 to the Company's audited consolidated financial statements filed with the 2012 Form 10-K. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $37.0 million as of September 29, 2013. As of September 29, 2013, the Company has recorded contingent consideration obligations relating to these acquisitions, with an estimated fair value of $2.9 million at September 29, 2013. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date.
	A reconciliation of the beginning and ending Level 3 net liabilities is as follows:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Balance beginning of period	$	(3,715	)	$	(7,315	)	$	(3,017	)	$	(20,298	)
	Additions	—			—			(1,100		)	—
	Amounts paid and foreign currency translation	31			3,771			95			17,417
	Change in fair value (included within selling, general and administrative expenses)	826			2,338			1,164			1,675
	Balance end of period	$	(2,858	)	$	(1,206	)	$	(2,858	)	$	(1,206	)
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
	The Company’s senior unsecured revolving credit facility, which provides for $700 million of revolving loans, had amounts outstanding, excluding letters of credit, of $248.0 million and $258.0 million as of September 29, 2013 and December 30, 2012, respectively. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first nine months of fiscal year 2013. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2.
	The Company’s 2015 Notes, with a face value of $150.0 million, had an aggregate carrying value of $150.0 million and a fair value of $159.9 million as of September 29, 2013. The 2015 Notes had an aggregate carrying value of $150.0 million and a fair value of $165.4 million as of December 30, 2012. The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount, and a fair value of $531.9 million as of September 29, 2013. The 2021 Notes had an aggregate carrying value of $497.2 million, net of $2.8 million of unamortized original issue discount, and a fair value of $558.3 million as of December 30, 2012. The fair values of the 2015 Notes and the 2021 Notes are estimated using market quotes from brokers, or are based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $40.5 million as of September 29, 2013 and approximated the fair value given the timing of the recognition of these obligations to the balance sheet date. As of September 29, 2013, the 2015 Notes, 2021 Notes and financing lease obligations were classified as Level 2.
	As of September 29, 2013, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Leases_Leases

Leases Leases	9 Months Ended
	Sep. 29, 2013
Leases [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	Leases
	On August 22, 2013, the Company sold one of its facilities located in Boston, Massachusetts for $49.5 million. Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and the Company has deferred $26.5 million of gains which will be amortized in operating expenses over the initial lease term of 15 years. Minimum rental commitments under the noncancelable operating lease are as follows: $3.2 million in fiscal year 2014, $3.2 million in fiscal year 2015, $3.3 million in fiscal year 2016, $3.4 million in fiscal year 2017, $3.5 million in fiscal year 2018 and $37.6 million in the aggregate thereafter. During the third quarter of fiscal year 2013, the Company amortized $0.2 million of deferred gains related to the lease. At September 29, 2013, $26.3 million of these deferred gains remained to be amortized.

Contingencies

Contingencies	9 Months Ended
	Sep. 29, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $6.9 million as of September 29, 2013, which represents management’s estimate of the total cost of the ultimate remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. This amount is not discounted and does not reflect the recovery of any amounts through insurance or indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
	Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint dated October 23, 2002 in the United States District Court for the Southern District of New York, Civil Action No. 02-8448, seeking injunctive and monetary relief against Amersham plc, Amersham BioSciences, PerkinElmer, Inc., PerkinElmer Life Sciences, Inc., Sigma-Aldrich Corporation, Sigma Chemical Company, Inc., Molecular Probes, Inc., and Orchid BioSciences, Inc. The complaint alleges that the Company breached its distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology, separately and together with the other defendants. The Company filed an answer and a counterclaim alleging that Enzo's patents are invalid. In 2007, after the court issued a decision in 2006 regarding the construction of the claims in Enzo's patents that effectively limited the coverage of certain of those claims and, the Company believes, excluded certain of the Company's products from the coverage of Enzo's patents, summary judgment motions were filed by the defendants. The case was assigned to a new district court judge in January 2009 and in March 2009, the new judge denied the pending summary judgment motions without prejudice and ordered a stay of the case until the federal appellate court decided Enzo's appeal of the judgment of the United States District Court for the District of Connecticut in Enzo Biochem vs. Applera Corp. and Tropix, Inc. (the “Connecticut Case”), which involved a number of the same patents and which could materially affect the scope of Enzo's case against the Company. In March 2010, the United States Court of Appeals for the Federal Circuit affirmed-in-part and reversed-in-part the judgment in the Connecticut Case. The district court permitted the Company and the other defendants to jointly file a motion for summary judgment on certain patent and other issues common to all of the defendants. On September 12, 2012, the court granted in part and denied in part the Company's motion for summary judgment of non-infringement. On December 21, 2012, the Company filed a second motion for summary judgment on claims that were not addressed in the first motion, which the court also granted in part and denied in part. The case is expected to go to trial in early 2014.
	The Company believes it has meritorious defenses to the matter described above, and it is contesting the action vigorously. While this matter is subject to uncertainty, in the opinion of the Company’s management, based on its review of the information available at this time, the resolution of this matter will not have a material adverse effect on the Company’s condensed consolidated financial statements.
	The Company is also subject to various other claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these other contingencies at September 29, 2013 should not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Business_Combinations_Tables

Business Combinations (Tables) (Haoyuan Biotech Co. [Member])	9 Months Ended
	Sep. 29, 2013
Haoyuan Biotech Co. [Member]	'
Business Acquisition [Line Items]	'
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed	'
	The total purchase price has been preliminarily allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Haoyuan
		(Preliminary)
		(In thousands)
	Fair value of business combination:
	Cash payments	$	38,000
	Contingent consideration	1,900
	Working capital and other adjustments	(2,729		)
	Less cash acquired	(175		)
	Total	$	36,996
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	2,389
	Property, plant and equipment	2,906
	Identifiable intangible assets:
	Core technology	17,700
	Trade names	400
	IPR&D	300
	Goodwill	19,682
	Deferred taxes	(2,656		)
	Liabilities assumed	(3,725		)
	Total	$	36,996

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 29, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of Gains and Losses on Disposition of Discontinued Operations	'
	The Company recorded the following gains and losses, which have been reported as a (loss) gain on disposition of discontinued operations:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Gain on disposition of Photoflash business	$	—		$	974		$	493		$	1,966
	Loss on disposition of other discontinued operations	(64		)	(76		)	(36		)	(51		)
	(Loss) gain on disposition of discontinued operations before income taxes	$	(64	)	$	898		$	457		$	1,915

Restructuring_and_Lease_Charge1

Restructuring and Lease Charges, Net (Tables)	9 Months Ended
	Sep. 29, 2013
Q3 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q3 2013 Plan activity for the nine months ended September 29, 2013:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Provision	$	394		$	138		$	532
	Amounts paid and foreign currency translation	—			(26		)	(26		)
	Balance at September 29, 2013	$	394		$	112		$	506
Q2 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q2 2013 Plan activity for the nine months ended September 29, 2013:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Provision	$	18,476		$	572		$	19,048
	Amounts paid and foreign currency translation	(3,824		)	(519		)	(4,343		)
	Balance at September 29, 2013	$	14,652		$	53		$	14,705
Q1 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q1 2013 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Provision	$	2,585
	Amounts paid and foreign currency translation	(2,371		)
	Balance at September 29, 2013	$	214
Q4 2012 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q4 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	2,682
	Amounts paid and foreign currency translation	(2,016		)
	Balance at September 29, 2013	$	666
Q3 2012 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q3 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	7,553
	Change in estimates	(546		)
	Amounts paid and foreign currency translation	(2,859		)
	Balance at September 29, 2013	$	4,148
Q2 2012 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q2 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	4,586
	Provision	2,052
	Amounts paid and foreign currency translation	(3,975		)
	Balance at September 29, 2013	$	2,663
Q1 2012 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q1 2012 Plan activity for the nine months ended September 29, 2013:
		Severance
		(In thousands)
	Balance at December 30, 2012	$	1,281
	Provision	30
	Amounts paid and foreign currency translation	(594		)
	Balance at September 29, 2013	$	717

Interest_and_Other_Expense_Inc1

Interest and Other Expense (Income), Net (Tables)	9 Months Ended
	Sep. 29, 2013
Other Income and Expenses [Abstract]	'
Interest and Other Expense (Income), Net	'
	Interest and other expense, net, consisted of the following:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Interest income	$	(119	)	$	(74	)	$	(288	)	$	(434	)
	Interest expense	11,704			11,360			35,310			34,136
	Other expense, net	755			586			2,223			2,358
	Total interest and other expense, net	$	12,340		$	11,872		$	37,245		$	36,060

Inventories_Net_Tables

Inventories, Net (Tables)	9 Months Ended
	Sep. 29, 2013
Inventory Disclosure [Abstract]	'
Schedule of Net Inventories	'
	Inventories as of September 29, 2013 and December 30, 2012 consisted of the following:
		September 29,		December 30,
		2013		2012
		(In thousands)
	Raw materials	$	101,562	$	74,924
	Work in progress	15,502		12,768
	Finished goods	161,287		159,996
	Total inventories, net	$	278,351	$	247,688

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 29, 2013
Earnings Per Share [Abstract]	'
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	'
	The following table reconciles the number of shares utilized in the earnings per share calculations:
		Three Months Ended		Nine Months Ended
		September 29,	September 30,	September 29,	September 30,
		2013	2012	2013	2012
		(In thousands)
	Number of common shares—basic	111,827	113,860	112,285	113,491
	Effect of dilutive securities:
	Stock options	997	830	987	827
	Restricted stock awards	291	308	244	247
	Number of common shares—diluted	113,115	114,998	113,516	114,565
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	465	1,381	493	1,448

Industry_Segment_Information_T

Industry Segment Information (Tables)	9 Months Ended
	Sep. 29, 2013
Segment Reporting [Abstract]	'
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	'
	Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Human Health
	Product revenue	$	227,167		$	225,029		$	682,164		$	671,576
	Service revenue	65,217			62,224			191,492			184,208
	Total revenue	292,384			287,253			873,656			855,784
	Operating income from continuing operations	43,901			34,398			98,997			82,962
	Environmental Health
	Product revenue	128,578			124,038			394,225			398,928
	Service revenue	103,315			98,313			305,071			287,572
	Total revenue	231,893			222,351			699,296			686,500
	Operating income from continuing operations	21,896			18,475			61,922			77,948
	Corporate
	Operating loss from continuing operations(1)	(8,601		)	(9,655		)	(28,158		)	(31,523		)
	Continuing Operations
	Product revenue	$	355,745		$	349,067		$	1,076,389		$	1,070,504
	Service revenue	168,532			160,537			496,563			471,780
	Total revenue	524,277			509,604			1,572,952			1,542,284
	Operating income from continuing operations	57,196			43,218			132,761			129,387
	Interest and other expense, net (see Note 5)	12,340			11,872			37,245			36,060
	Income from continuing operations before income taxes	$	44,856		$	31,346		$	95,516		$	93,327
	____________________________
	(1)	The expenses related to the mark-to-market adjustment on postretirement benefit plans have been included in the Corporate operating loss from continuing operations, and together constituted a pre-tax gain of $0.05 million and a pre-tax loss of $1.2 million for the nine months ended September 29, 2013 and September 30, 2012, respectively. There were no expenses related to the mark-to-market adjustment on postretirement benefit plans for either the three months ended September 29, 2013 or September 30, 2012.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 29, 2013
Stockholders' Equity Note [Abstract]	'
Components of Accumulated Other Comprehensive Loss	'
	The components of accumulated other comprehensive income consisted of the following:
		September 29,			December 30,
		2013			2012
		(In thousands)
	Foreign currency translation adjustments	$	69,230		$	67,527
	Unrecognized prior service costs, net of income taxes	2,087			2,087
	Unrealized and realized losses on derivatives, net of income taxes	(1,995		)	(2,892		)
	Unrealized net losses on securities, net of income taxes	(119		)	(129		)
	Accumulated other comprehensive income	$	69,203		$	66,593

Stock_Plans_Tables

Stock Plans (Tables)	9 Months Ended
	Sep. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	'
	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and nine months ended September 29, 2013 and September 30, 2012:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Cost of product and service revenue	$	337		$	327		$	958		$	906
	Research and development expenses	203			186			629			547
	Selling, general and administrative expenses	3,241			4,588			9,836			13,899
	Total stock-based compensation expense	$	3,781		$	5,101		$	11,423		$	15,352
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	'
	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
		Three and Nine Months Ended
		September 29,		September 30,
		2013		2012
	Risk-free interest rate	0.9	%	0.6	%
	Expected dividend yield	0.8	%	1.2	%
	Expected lives	5 years		4 years
	Expected stock volatility	38.5	%	38.7	%
Summary of Stock Option Activity	'
	The following table summarizes stock option activity for the nine months ended September 29, 2013:
		Number		Weighted-			Weighted-Average		Total
		of		Average			Remaining		Intrinsic
		Shares		Price			Contractual Term		Value
		(In thousands)					(In years)		(In millions)
	Outstanding at December 30, 2012	4,266		$	21.64
	Granted	518		33.62
	Exercised	(721	)	21.2
	Canceled	(7	)	22.63
	Forfeited	(325	)	22.82
	Outstanding at September 29, 2013	3,731		$	23.29		3.6		$	46.9
	Exercisable at September 29, 2013	2,590		$	20.82		2.7		$	38.9
	Vested and expected to vest in the future	3,683		$	22.93		3.6		$	46.5
Summary of Restricted Stock Award Activity	'
	The following table summarizes restricted stock award activity for the nine months ended September 29, 2013:
		Number of		Weighted-
		Shares		Average
				Grant-
				Date Fair
				Value
		(In thousands)
	Nonvested at December 30, 2012	781		$	24.71
	Granted	277		33.74
	Vested	(327	)	23.23
	Forfeited	(70	)	28.67
	Nonvested at September 29, 2013	661		$	28.8

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 29, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill for the period ended September 29, 2013 from December 30, 2012 were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 30, 2012	$	1,632,487		$	490,301		$	2,122,788
	Foreign currency translation	7,069			556			7,625
	Acquisitions and other	—			638			638
	Balance at September 29, 2013	$	1,639,556		$	491,495		$	2,131,051
Identifiable Intangible Asset Balances	'
	Identifiable intangible asset balances at September 29, 2013 and December 30, 2012 by category were as follows:
		September 29,			December 30,
		2013			2012
		(In thousands)
	Patents	$	101,831		$	107,969
	Less: Accumulated amortization	(85,789		)	(89,954		)
	Net patents	16,042			18,015
	Trade names and trademarks	36,430			37,694
	Less: Accumulated amortization	(15,784		)	(13,886		)
	Net trade names and trademarks	20,646			23,808
	Licenses	79,208			80,607
	Less: Accumulated amortization	(50,509		)	(47,368		)
	Net licenses	28,699			33,239
	Core technology	408,342			407,545
	Less: Accumulated amortization	(271,440		)	(248,510		)
	Net core technology	136,902			159,035
	Customer relationships	325,533			327,637
	Less: Accumulated amortization	(122,499		)	(108,384		)
	Net customer relationships	203,034			219,253
	IPR&D	7,510			7,463
	Less: Accumulated amortization	(2,000		)	(1,496		)
	Net IPR&D	5,510			5,967
	Net amortizable intangible assets	410,833			459,317
	Non-amortizing intangible assets:
	Trade names and trademarks	70,584			70,584
	Total	$	481,417		$	529,901

Warranty_Reserves_Tables

Warranty Reserves (Tables)	9 Months Ended
	Sep. 29, 2013
Product Warranties Disclosures [Abstract]	'
Warranty Reserve Activity	'
	Warranty reserve activity for the three and nine months ended September 29, 2013 and September 30, 2012 is summarized below:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Balance beginning of period	$	10,451		$	10,625		$	11,003		$	10,412
	Provision charged to income	4,160			4,063			12,673			12,960
	Payments	(4,113		)	(4,304		)	(12,781		)	(13,344		)
	Adjustments to previously provided warranties, net	268			221			(54		)	708
	Foreign currency translation and acquisitions	122			154			47			23
	Balance end of period	$	10,888		$	10,759		$	10,888		$	10,759

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 29, 2013
Compensation and Retirement Disclosure [Abstract]	'
Components of Net Periodic Benefit Cost (Credit)	'
	The following table summarizes the components of net periodic benefit (credit) cost for the Company’s various defined benefit employee pension and postretirement plans for the three and nine months ended September 29, 2013 and September 30, 2012:
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Three Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Service cost	$	916		$	977		$	28		$	28
	Interest cost	5,312			5,774			36			37
	Expected return on plan assets	(6,261		)	(5,140		)	(241		)	(219		)
	Amortization of prior service costs	(67		)	(60		)	—			—
	Net periodic benefit (credit) cost	$	(100	)	$	1,551		$	(177	)	$	(154	)
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Service cost	$	2,757		$	2,934		$	85		$	85
	Interest cost	15,925			17,381			107			111
	Expected return on plan assets	(18,778		)	(15,422		)	(723		)	(657		)
	Amortization of prior service	(201		)	(180		)	—			—
	Net periodic benefit (credit) cost	$	(297	)	$	4,713		$	(531	)	$	(461	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 29, 2013
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	'
	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of September 29, 2013 and December 30, 2012 classified in one of the three classifications described above:
		Fair Value Measurements at September 29, 2013 Using:
		Total Carrying Value at September 29, 2013			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,220		$	1,220		$	—		$	—
	Foreign exchange derivative assets	246			—			246			—
	Foreign exchange derivative liabilities	(207		)	—			(207		)	—
	Contingent consideration	(2,858		)	—			—			(2,858		)
		Fair Value Measurements at December 30, 2012 Using:
		Total Carrying Value at December 30, 2012			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,149		$	1,149		$	—		$	—
	Foreign exchange derivative assets	274			—			274			—
	Foreign exchange derivative liabilities	(294		)	—			(294		)	—
	Contingent consideration	(3,017		)	—			—			(3,017		)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	'
	A reconciliation of the beginning and ending Level 3 net liabilities is as follows:
		Three Months Ended						Nine Months Ended
		September 29,			September 30,			September 29,			September 30,
		2013			2012			2013			2012
		(In thousands)
	Balance beginning of period	$	(3,715	)	$	(7,315	)	$	(3,017	)	$	(20,298	)
	Additions	—			—			(1,100		)	—
	Amounts paid and foreign currency translation	31			3,771			95			17,417
	Change in fair value (included within selling, general and administrative expenses)	826			2,338			1,164			1,675
	Balance end of period	$	(2,858	)	$	(1,206	)	$	(2,858	)	$	(1,206	)

Business_Combinations_Narrativ

Business Combinations (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended				1 Months Ended	12 Months Ended
	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012	Dec. 30, 2012	Jun. 30, 2013	Jul. 01, 2012	Jan. 01, 2012	Nov. 30, 2012	Dec. 30, 2012	Dec. 30, 2012
									Human Health [Member]	Trade Names [Member]	Core Technology [Member]
									Haoyuan Biotech Co. [Member]	Human Health [Member]	Human Health [Member]
										Haoyuan Biotech Co. [Member]	Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Cash paid to the shareholders	'	'	'	'	'	'	'	'	$38,000,000	'	'
Working capital adjustments	'	'	'	'	'	'	'	'	2,729,000	'	'
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	'	'	'	'	'	'	'	'	1,900,000	'	'
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	'	'	'	'	'	'	'	'	'	'8 years	'8 years
Total transaction costs	0	300,000	100,000	600,000	'	'	'	'	'	'	'
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	'	'	'	'	'1 year	'	'	'	'	'	'
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	37,000,000	'	37,000,000	'	'	'	'	'	30,000,000	'	'
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$2,858,000	$1,206,000	$2,858,000	$1,206,000	$3,017,000	$3,715,000	$7,315,000	$20,298,000	'	'	'
Business Combination, Contingent Consideration Arrangements, Maximum Period	'	'	'3 years	'	'	'	'	'	'	'	'
Business Combination, Contingent Consideration Arrangements, Description	'	'	'Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date.	'	'	'	'	'	'	'	'

Business_Combinations_Fair_Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) (USD $)	Sep. 29, 2013	Dec. 30, 2012	Sep. 29, 2013	Dec. 30, 2012	Nov. 30, 2012	Dec. 30, 2012	Nov. 30, 2012	Dec. 30, 2012	Nov. 30, 2012	Nov. 30, 2012
In Thousands, unless otherwise specified			Human Health [Member]	Human Health [Member]	Human Health [Member]	Human Health [Member]	Human Health [Member]	Human Health [Member]	Human Health [Member]	Human Health [Member]
					Haoyuan Biotech Co. [Member]	Core Technology [Member]	Core Technology [Member]	Trade Names [Member]	Trade Names [Member]	In-process Research and Development [Member]
						Haoyuan Biotech Co. [Member]	Haoyuan Biotech Co. [Member]	Haoyuan Biotech Co. [Member]	Haoyuan Biotech Co. [Member]	Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life	'	'	'	'	'	'8 years	'	'8 years	'	'
Business Acquisition, Cost of Acquired Entity, Cash Paid	'	'	'	'	$38,000	'	'	'	'	'
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	'	'	'	'	1,900	'	'	'	'	'
Working capital adjustments	'	'	'	'	-2,729	'	'	'	'	'
Less: cash acquired	'	'	'	'	175	'	'	'	'	'
Business Combination, Consideration Transferred	'	'	'	'	36,996	'	'	'	'	'
Current assets	'	'	'	'	2,389	'	'	'	'	'
Property, plant and equipment	'	'	'	'	2,906	'	'	'	'	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	'	'	'	'	'	'	17,700	'	400	300
Goodwill	2,131,051	2,122,788	1,639,556	1,632,487	19,682	'	'	'	'	'
Deferred taxes	'	'	'	'	-2,656	'	'	'	'	'
Liabilities assumed	'	'	'	'	-3,725	'	'	'	'	'
Total	'	'	'	'	$36,996	'	'	'	'	'

Discontinued_Operations_Narrat

Discontinued Operations (Narrative) (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2010	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	'	($64,000)	$898,000	$457,000	$1,915,000
(Benefit from) provision for income taxes on discontinued operations and dispositions	'	37,000	293,000	-358,000	752,000
Photoflash Business [Member]	'	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Proceed from business divestiture	13,500,000	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	'	0	974,000	493,000	1,966,000
Other Discontinued Operations [Member]	'	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	'	($64,000)	($76,000)	($36,000)	($51,000)

Discontinued_Operations_Schedu

Discontinued Operations (Schedule of Gains and Losses on Disposition of Discontinued Operations) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	($64)	$898	$457	$1,915
Photoflash Business [Member]	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	0	974	493	1,966
Other Discontinued Operations [Member]	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	($64)	($76)	($36)	($51)

Restructuring_and_Lease_Charge2

Restructuring and Lease Charges, Net (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Sep. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

Sep. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Previous restructuring and integration plans [Member]

Previous restructuring and integration plans [Member]

Contract Termination [Member]

Human Health [Member]

Severance [Member]

Facility Closing [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Facility Closing [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and lease charges, net

$1,126,000

$9,672,000

$23,713,000

$21,034,000

'

$532,000

$500,000

$394,000

$138,000

'

$19,048,000

$10,300,000

$8,800,000

$18,476,000

$572,000

'

$2,300,000

$200,000

$2,585,000

'

'

$600,000

$2,400,000

'

'

'

$3,900,000

'

$3,900,000

'

'

'

'

$2,100,000

$7,200,000

'

$200,000

$2,052,000

'

'

'

$5,400,000

$1,000,000

'

'

'

'

'

Restructuring and Related Cost, Remaining Cost

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

Restructuring Reserve, Accrual Adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-300,000

'

-300,000

-546,000

'

'

'

'

-100,000

'

'

'

'

'

'

'

30,000

'

'

-300,000

300,000

Number of employees reduced

'

'

'

'

'

30

'

'

'

265

'

'

'

'

'

62

'

'

'

'

54

'

'

'

'

66

'

'

'

'

'

'

203

'

'

'

'

'

'

112

'

'

'

'

'

'

'

'

Remaining payments

27,739,000

'

27,739,000

'

21,364,000

506,000

'

394,000

112,000

'

14,705,000

'

'

14,652,000

53,000

'

'

'

'

214,000

'

'

'

666,000

2,682,000

'

'

'

'

'

4,148,000

7,553,000

'

'

'

'

'

2,663,000

4,586,000

'

'

'

'

717,000

1,281,000

8,900,000

'

100,000

Restructuring Reserve, Settled with Cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

Payments for Restructuring

'

'

'

'

'

$26,000

'

$0

$26,000

'

$4,343,000

'

'

$3,824,000

$519,000

'

'

'

'

$2,371,000

'

'

'

$2,016,000

'

'

'

'

'

'

$2,859,000

'

'

'

'

'

'

$3,975,000

'

'

'

'

'

$594,000

'

$1,900,000

'

'

Restructuring_and_Lease_Charge3

Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Mar. 31, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Mar. 31, 2013

Dec. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Mar. 31, 2013

Dec. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Dec. 30, 2012

Dec. 30, 2012

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Previous restructuring and integration plans [Member]

Previous restructuring and integration plans [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Severance [Member]

Facility Closing [Member]

Severance [Member]

Facility Closing [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Q3 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q4 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q3 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q2 2012 Restructuring Plan [Member]

Q1 2012 Restructuring Plan [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and lease charges, net

$1,126

$9,672

$23,713

$21,034

$532

$394

$138

$19,048

$18,476

$572

$2,585

'

'

'

$2,052

'

'

'

$500

$10,300

$2,300

$600

$3,900

'

$2,100

$7,200

$5,400

$8,800

$200

$2,400

$3,900

'

'

$200

$1,000

Restructuring Reserve [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at beginning of period

'

'

21,364

'

'

'

'

'

'

'

'

'

2,682

7,553

4,586

1,281

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Reserve, Accrual Adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

-546

'

30

'

-300

'

'

'

'

'

-300

'

'

'

'

'

'

'

-300

-100

'

'

Amounts paid and foreign currency translation

'

'

'

'

-26

0

-26

-4,343

-3,824

-519

'

-2,371

-2,016

-2,859

-3,975

-594

-1,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at end of period

$27,739

'

$27,739

'

$506

$394

$112

$14,705

$14,652

$53

'

$214

$666

$4,148

$2,663

$717

$8,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest_and_Other_Expense_Inc2

Interest and Other Expense (Income), Net (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Other Income and Expenses [Abstract]	'	'	'	'
Interest income	($119)	($74)	($288)	($434)
Interest expense	11,704	11,360	35,310	34,136
Other expense, net	755	586	2,223	2,358
Total interest and other expense, net	$12,340	$11,872	$37,245	$36,060

Inventories_Net_Details

Inventories, Net (Details) (USD $)	Sep. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$101,562	$74,924
Work in progress	15,502	12,768
Finished goods	161,287	159,996
Total inventories, net	$278,351	$247,688

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Jan. 01, 2012	Sep. 29, 2013	Jan. 01, 2012
Income Tax Contingency [Line Items]	'	'	'	'
Unrecognized tax benefits, gross	'	'	$48.50	'
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	'	'	42.1	'
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations	-9.4	'	'	'
Uncertain tax positions including accrued interest, net of tax benefits and penalties, to be resolved within the next year	'	'	11.5	'
Unremitted Earnings Planned To Be Repatriated	'	'	'	350
Increase (decrease) to tax provision in discontinued operations	'	79.7	2.4	'
Repatriated Foreign Earnings	'	'	350	'
Open Tax Years by Major Tax Jurisdiction, Begin Date	'	'	'2006	'
Tax Adjustments, Settlements, and Unusual Provisions	'	'	($15.60)	'

Debt_Details

Debt (Details) (USD $)

9 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

Sep. 29, 2013

Dec. 30, 2012

30-May-08

Sep. 29, 2013

Dec. 30, 2012

Oct. 25, 2011

Sep. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Dec. 30, 2012

Sep. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

2015 Notes [Member]

2015 Notes [Member]

2015 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

Financing Lease Obligations [Member]

Financing Lease Obligations [Member]

Financing Lease Obligations [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Treasury Rate [Member]

Base Rate Option Three [Member]

Base Rate Option Two [Member]

Eurocurrency Rate [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$700,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured revolving credit facility, expiry date

16-Dec-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Letters of credit issued and outstanding

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

'

'

'

Line of Credit Facility, Remaining Borrowing Capacity

440,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate terms under amended senior unsecured revolving credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate is the higher of (i)B the rate of interest in effect for such day as publicly announced from time to time by Bank of America, N.A. as its "prime rate," (ii)B the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%.

'

'

'

Weighted average interest rates under amended senior unsecured revolving credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'The Eurocurrency margin as of September 29, 2013 was 130 basis points. The weighted average Eurocurrency interest rate as of September 29, 2013 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.48%, which is the interest applicable to borrowings outstanding under the Eurocurrency rate as of SeptemberB 29, 2013.

'

'

'

Description of variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Federal Funds

'Eurocurrency

Basis spread on variable rate

'

'

'

'

'

'

'

'

0.45%

'

'

'

'

1.00%

0.50%

1.30%

Weighted average Eurocurrency interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.18%

Weighted average effective Eurocurrency rate, including the margin

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.48%

Aggregate borrowings under the amended facility

248,000,000

258,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured senior notes, interest rate percent

'

'

6.00%

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

Unsecured senior notes, face value

'

'

150,000,000

150,000,000

'

500,000,000

500,000,000

'

'

'

'

'

'

'

'

'

Gross proceeds from the issuance of debt instrument

'

'

150,000,000

'

'

496,900,000

'

'

'

'

'

'

'

'

'

'

Senior unsecured notes issuance as percentage of principal amount

'

'

'

'

'

99.37%

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

3,100,000

2,600,000

2,800,000

'

'

'

'

'

'

'

'

Long-term Debt, Gross

'

'

'

150,000,000

150,000,000

'

497,400,000

497,200,000

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

'

30-May-15

'

'

25-Nov-21

'

'

'

'

'

'

'

'

'

'

Percentage of redemption of senior notes on or after August 15, 2021

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes

'

'

'

'

'

101.00%

'

'

'

'

'

'

'

'

'

'

Initial Fair Value of Other Long-term Debt Related to Financing Lease Obligations

'

'

'

'

'

'

'

'

'

'

'

29,300,000

'

'

'

'

Other Long-term Debt

'

'

'

'

'

'

'

'

'

40,500,000

34,600,000

'

'

'

'

'

Other Long-term Debt, Current

'

'

'

'

'

'

'

'

'

2,600,000

1,700,000

'

'

'

'

'

Other Long-term Debt, Noncurrent

'

'

'

'

'

'

'

'

'

37,900,000

32,900,000

'

'

'

'

'

Maximum Additional Financing Lease Obligations

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

Additional Financing Lease Obligations, funded by lessors

'

'

'

'

'

'

'

'

'

$11,500,000

'

'

'

'

'

'

Earnings_Per_Share_Schedule_of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Number of common shares-basic	111,827	113,860	112,285	113,491
Effect of dilutive securities, Stock options	997	830	987	827
Effect of dilutive securities, Restricted stock	291	308	244	247
Number of common shares-diluted	113,115	114,998	113,516	114,565
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	465	1,381	493	1,448

Industry_Segment_Information_I

Industry Segment Information Industry Segment Information Narrative (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
			segments
Industry Segment Information Narrative [Abstract]	'	'	'	'
Defined Benefit Plan, Recognized Net (Gain) Loss on Mark-to-Market	$0	$0	($0.05)	$1.20
Number of Operating Segment	'	'	2	'

Industry_Segment_Information_S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Segment Reporting [Abstract]	'	'	'	'
Defined Benefit Plan, Recognized Net (Gain) Loss on Mark-to-Market	$0	$0	($50,000)	$1,200,000
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	524,277,000	509,604,000	1,572,952,000	1,542,284,000
Operating income (loss) from continuing operations	57,196,000	43,218,000	132,761,000	129,387,000
Interest and other expense, net	12,340,000	11,872,000	37,245,000	36,060,000
Income from continuing operations before income taxes	44,856,000	31,346,000	95,516,000	93,327,000
Sales Revenue, Goods, Net	355,745,000	349,067,000	1,076,389,000	1,070,504,000
Sales Revenue, Services, Net	168,532,000	160,537,000	496,563,000	471,780,000
Human Health [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	292,384,000	287,253,000	873,656,000	855,784,000
Operating income (loss) from continuing operations	43,901,000	34,398,000	98,997,000	82,962,000
Sales Revenue, Goods, Net	227,167,000	225,029,000	682,164,000	671,576,000
Sales Revenue, Services, Net	65,217,000	62,224,000	191,492,000	184,208,000
Environmental Health [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	231,893,000	222,351,000	699,296,000	686,500,000
Operating income (loss) from continuing operations	21,896,000	18,475,000	61,922,000	77,948,000
Sales Revenue, Goods, Net	128,578,000	124,038,000	394,225,000	398,928,000
Sales Revenue, Services, Net	103,315,000	98,313,000	305,071,000	287,572,000
Corporate [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Operating income (loss) from continuing operations	($8,601,000)	($9,655,000)	($28,158,000)	($31,523,000)

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended								9 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 29, 2013	Sep. 29, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 30, 2012	Sep. 30, 2012	Jul. 01, 2012	Apr. 01, 2012	Sep. 29, 2013	Oct. 24, 2012
Stockholders' Equity Note [Abstract]	'	'	'	'	'	'	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax	'	'	'	'	'	'	'	'	($1.50)	'
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax	'	'	'	'	'	'	'	'	0.6	'
Stock repurchase program, number of shares authorized to be repurchased	'	'	'	'	'	'	'	'	'	6,000,000
Number of common stock repurchased in open market	'	'	'	'	'	'	'	'	3,600,000	'
Aggregate cost of repurchased common stock	'	'	'	'	'	'	'	'	123	'
Stock repurchase program, number of shares remained available for repurchase	'	2,400,000	'	'	'	'	'	'	2,400,000	'
Repurchased shares of common stock to satisfy statutory tax withholding obligation requirements	'	'	'	'	'	'	'	'	122,015	'
Aggregate cost of repurchased common stock to satisfy statutory tax withholding obligation requirements	'	'	'	'	'	'	'	'	4.2	'
Cash dividends (per share)	$0.07	$0.07	$0.07	$0.07	$0.07	$0.07	$0.07	$0.07	'	'
Dividends Payable, Amount	'	$7.90	'	'	'	'	'	'	$7.90	'

Stockholders_Equity_Components

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) (USD $)	Sep. 29, 2013	Dec. 30, 2012	31-May-08
In Thousands, unless otherwise specified
Stockholders' Equity Note [Abstract]	'	'	'
Foreign currency translation adjustments, net of income taxes	$69,230	$67,527	'
Unrecognized losses and prior service costs, net of income taxes	2,087	2,087	'
Unrealized net losses on securities, net of income taxes	-119	-129	'
Unrealized and realized losses on derivatives, net of income taxes	-1,995	-2,892	-8,400
Accumulated other comprehensive loss	$69,203	$66,593	'

Stock_Plans_Narrative_Details

Stock Plans (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Sep. 30, 2012

Jul. 01, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

plan

Employee Stock Purchase Plan [Member]

Stock Awards [Member]

Stock Awards [Member]

Stock Awards [Member]

Stock Awards [Member]

Stock Awards [Member]

Stock Awards [Member]

Performance Units [Member]

Performance Units [Member]

Performance Units [Member]

Performance Units [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Restricted Stock Awards [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

2009 Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Former Stock-based Compensation Plans

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares authorized under plan

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

Total income tax benefit recognized for stock-based compensation

$1,200,000

$1,600,000

$3,600,000

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation costs capitalized as part of inventory

'

'

300,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options related excess tax benefit, classified as a financing cash activity

'

'

0

1,767,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average grant-date fair value of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$7.71

$10.82

$7.36

'

Total intrinsic value of options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,200,000

3,900,000

10,300,000

9,100,000

'

Cash received from option exercises

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,300,000

22,900,000

'

Shares/units granted

'

'

'

'

89,521

'

3,263

'

3,580

'

955

'

'

98,056

122,675

'

'

277,000

'

'

'

'

'

'

'

Weighted-average grant-date fair value of stock granted (per share)

'

'

'

'

$30.51

'

'

'

'

$30.65

$27.87

'

'

$34.06

$26.18

$36.11

$27.06

$33.74

$25.85

'

'

'

'

'

'

Fair value of restricted stock awards vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

100,000

7,600,000

4,200,000

'

'

'

'

'

'

Total pre-tax stock-based compensation expense

3,781,000

5,101,000

11,423,000

15,352,000

'

0

'

0

'

700,000

700,000

1,000,000

1,900,000

1,900,000

4,900,000

1,700,000

1,900,000

5,600,000

6,100,000

'

1,100,000

1,200,000

3,200,000

3,700,000

'

Awards/units outstanding

'

'

'

'

'

'

'

'

'

'

'

282,044

'

282,044

'

661,000

'

661,000

'

781,000

'

'

'

'

'

Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent

'

'

'

'

'

'

'

'

'

'

'

5,400,000

'

5,400,000

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,800,000

'

$10,800,000

'

'

$6,800,000

'

$6,800,000

'

'

Weighted-average period for recognition of unrecognized compensation cost, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 5 months

'

'

'

'

'1 year 11 months

'

'

Shares available for grant under employee stock purchase plan

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Plans_Summary_of_Total_C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	$3,781	$5,101	$11,423	$15,352
Cost of sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	337	327	958	906
Research and development expenses [Member ]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	203	186	629	547
Selling, general and administrative and other expenses [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	$3,241	$4,588	$9,836	$13,899

Stock_Plans_WeightedAverage_As

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	9 Months Ended
	Sep. 29, 2013	Sep. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Risk-free interest rate	0.90%	0.60%
Expected dividend yield	0.80%	1.20%
Expected lives, years	'5 years	'4 years
Expected stock volatility	38.50%	38.70%

Stock_Plans_Summary_of_Stock_O

Stock Plans (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 29, 2013
Stock option activity	'
Number of Shares, Outstanding at beginning of period	4,266
Number of Shares, Granted	518
Number of Shares, Exercised	-721
Number of Shares, Canceled	-7
Number of Shares, Forfeited	-325
Number of Shares, Outstanding at end of period	3,731
Number of Shares, Exercisable at end of period	2,590
Number of Shares, Vested and expected to vest in the future	3,683
Weighted-Average Price, Outstanding at beginning of period	$21.64
Weighted-Average Price, Granted	$33.62
Weighted-Average Price, Exercised	$21.20
Weighted-Average Price, Canceled	$22.63
Weighted-Average Price, Forfeited	$22.82
Weighted-Average Price, Outstanding at end of period	$23.29
Weighted-Average Price, Exercisable at end of period	$20.82
Weighted-Average Price, Vested and expected to vest in the future	$22.93
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period	'3 years 7 months
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period	'2 years 8 months
Weighted-Average Remaining Contractual Term in Years, Vested and expected to vest in the future	'3 years 7 months
Total Intrinsic Value, Outstanding at end of period	$46.90
Total Intrinsic Value, Exercisable at end of period	38.9
Total Intrinsic Value, Vested and expected to vest in the future	$46.50

Stock_Plans_Summary_of_Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) (Restricted Stock Awards [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Restricted Stock Awards [Member]	'	'	'	'
Restricted stock award activity	'	'	'	'
Number of Shares, Nonvested at beginning of period	'	'	781,000	'
Number of Shares, Granted	'	'	277,000	'
Number of Shares, Vested	'	'	-327,000	'
Number of Shares, Forfeited	'	'	-70,000	'
Number of Shares, Nonvested at end of period	661,000	'	661,000	'
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period	'	'	$24.71	'
Weighted-Average Grant-Date Fair Value, Granted	$36.11	$27.06	$33.74	$25.85
Weighted-Average Grant-Date Fair Value, Vested	'	'	$23.23	'
Weighted-Average Grant-Date Fair Value, Forfeited	'	'	$28.67	'
Weighted-Average Grant-Date Fair Value, Nonvested at end of period	$28.80	'	$28.80	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets, Net (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012	Dec. 29, 2013	Dec. 30, 2012
Goodwill and Intangible Assets Net [Line Items]	'	'	'	'	'	'
Reallocation of Goodwill Resulting from Realignment Within Operating Segments	'	'	'	'	'	$215,700,000
Change in any one of the input assumptions for the various reporting units	'	'	'	'	10.00%	'
Total amortization expense related to finite-lived intangible assets	23,100,000	22,000,000	67,900,000	68,700,000	'	'
Future Amortization Expense, Year One	21,900,000	'	21,900,000	'	'	'
Future Amortization Expense, Year Two	81,100,000	'	81,100,000	'	'	'
Future Amortization Expense, Year Three	67,700,000	'	67,700,000	'	'	'
Future Amortization Expense, Year Four	58,800,000	'	58,800,000	'	'	'
Future Amortization Expense, Year Five	47,700,000	'	47,700,000	'	'	'
Finite-Lived Intangible Assets, Net	410,833,000	'	410,833,000	'	'	459,317,000
Minimum [Member]	'	'	'	'	'	'
Goodwill and Intangible Assets Net [Line Items]	'	'	'	'	'	'
Long-term terminal growth rates for reporting units	'	'	'	'	4.50%	'
Discount rates for reporting units	'	'	'	'	10.50%	'
Maximum [Member]	'	'	'	'	'	'
Goodwill and Intangible Assets Net [Line Items]	'	'	'	'	'	'
Long-term terminal growth rates for reporting units	'	'	'	'	6.00%	'
Discount rates for reporting units	'	'	'	'	12.00%	'
Other Asset Acquisitions [Member]	'	'	'	'	'	'
Goodwill and Intangible Assets Net [Line Items]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net	7,000,000	6,800,000	7,000,000	6,800,000	'	'
Prepaid Royalties	27,800,000	'	27,800,000	'	'	25,000,000
Prepaid Royalties To Be Paid Within One Year	$13,000,000	'	$13,000,000	'	'	'

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013
Changes in the carrying amount of goodwill	'
Balance at beginning of period	$2,122,788
Foreign currency translation	7,625
Acquisitions, earn outs and other	638
Balance at end of period	2,131,051
Human Health [Member]	'
Changes in the carrying amount of goodwill	'
Balance at beginning of period	1,632,487
Foreign currency translation	7,069
Acquisitions, earn outs and other	0
Balance at end of period	1,639,556
Environmental Health [Member]	'
Changes in the carrying amount of goodwill	'
Balance at beginning of period	490,301
Foreign currency translation	556
Acquisitions, earn outs and other	638
Balance at end of period	$491,495

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) (USD $)	Sep. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Net amortizable intangible assets	$410,833	$459,317
Totals	481,417	529,901
Patents [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	101,831	107,969
Less: Accumulated amortization	-85,789	-89,954
Net amortizable intangible assets	16,042	18,015
Trade Names And Trademarks [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	36,430	37,694
Less: Accumulated amortization	-15,784	-13,886
Net amortizable intangible assets	20,646	23,808
Non-amortizing intangible assets	70,584	70,584
Licensing Agreements [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	79,208	80,607
Less: Accumulated amortization	-50,509	-47,368
Net amortizable intangible assets	28,699	33,239
Core Technology [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	408,342	407,545
Less: Accumulated amortization	-271,440	-248,510
Net amortizable intangible assets	136,902	159,035
Customer Relationships [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	325,533	327,637
Less: Accumulated amortization	-122,499	-108,384
Net amortizable intangible assets	203,034	219,253
In-process Research and Development [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	7,510	7,463
Less: Accumulated amortization	-2,000	-1,496
Net amortizable intangible assets	$5,510	$5,967

Warranty_Reserves_Details

Warranty Reserves (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Warranty reserve activity	'	'	'	'
Balance beginning of period	$10,451	$10,625	$11,003	$10,412
Provision charged to income	4,160	4,063	12,673	12,960
Payments	-4,113	-4,304	-12,781	-13,344
Adjustments to previously provided warranties, net	268	221	-54	708
Foreign currency translation and acquisitions	122	154	47	23
Balance end of period	$10,888	$10,759	$10,888	$10,759

Employee_Benefit_Plans_Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Defined Benefit Pension Benefits [Member]	'	'	'	'
Components of net periodic benefit cost (credit)	'	'	'	'
Service cost	$916,000	$977,000	$2,757,000	$2,934,000
Interest cost	5,312,000	5,774,000	15,925,000	17,381,000
Expected return on plan assets	-6,261,000	-5,140,000	-18,778,000	-15,422,000
Amortization of prior service	-67,000	-60,000	-201,000	-180,000
Net periodic benefit cost (credit)	-100,000	1,551,000	-297,000	4,713,000
Defined Benefit Pension Plan in the United States [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Defined Benefit Plan, Contributions by Employer	'	'	37,000,000	'
Foreign Pension Plans, Defined Benefit [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Defined Benefit Plan, Contributions by Employer	'	'	17,900,000	'
Postretirement Medical Benefits [Member]	'	'	'	'
Components of net periodic benefit cost (credit)	'	'	'	'
Service cost	28,000	28,000	85,000	85,000
Interest cost	36,000	37,000	107,000	111,000
Expected return on plan assets	-241,000	-219,000	-723,000	-657,000
Amortization of prior service	0	0	0	0
Net periodic benefit cost (credit)	-177,000	-154,000	-531,000	-461,000
United Kingdom Pension Plans, Defined Benefit [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Defined Benefit Plan, Contributions by Employer	'	'	$10,000,000	'

Derivatives_And_Hedging_Activi1

Derivatives And Hedging Activities (Details)

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

Sep. 29, 2013

Dec. 30, 2012

31-May-08

Sep. 29, 2013

Sep. 29, 2013

Dec. 30, 2012

Sep. 30, 2012

Dec. 30, 2012

Sep. 29, 2013

Sep. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

Sep. 29, 2013

Dec. 30, 2012

USD ($)

USD ($)

USD ($)

European And Asian Currencies [Member]

Fair Value Hedging [Member]

Fair Value Hedging [Member]

Fair Value Hedging [Member]

Cash Flow Hedging [Member]

Interest Rate Contract [Member]

Interest Rate Contract [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Other Observable Inputs (Level 2) [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

Interest Expense [Member]

Interest Expense [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's business conducted outside United States

60.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum maturity period for foreign exchange contracts, in months

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

Foreign Currency Contract, Asset, Fair Value Disclosure

'

'

'

'

'

'

'

'

'

'

($246,000)

($274,000)

($246,000)

($274,000)

Duration of foreign currency derivative contract, days

'30 days

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount of Cash Flow Hedge Instruments

'

'

'

'

110,000,000

64,300,000

66,600,000

50,000,000

'

'

'

'

'

'

Settlement of forward interest rate contracts with notional amounts

'

'

150,000,000

'

'

'

'

'

'

'

'

'

'

'

Accumulated derivative losses related to effective cash flow hedges in accumulated other comprehensive loss, net of taxes

-1,995,000

-2,892,000

-8,400,000

'

'

'

'

'

'

'

'

'

'

'

Accumulated derivative losses related to effective cash flow hedges in accumulated other comprehensive loss, tax

1,300,000

'

5,400,000

'

'

'

'

'

'

'

'

'

'

'

Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion

'

'

'

'

'

'

'

'

1,500,000

1,500,000

'

'

'

'

Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)

9 Months Ended

Sep. 29, 2013

Jun. 30, 2013

Dec. 30, 2012

Sep. 30, 2012

Jul. 01, 2012

Jan. 01, 2012

Sep. 29, 2013

Dec. 30, 2012

30-May-08

Sep. 29, 2013

Dec. 30, 2012

Oct. 25, 2011

Sep. 29, 2013

2015 Notes [Member]

2015 Notes [Member]

2015 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

Financing Lease Obligations [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

$700,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

37,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value

2,858,000

3,715,000

3,017,000

1,206,000

7,315,000

20,298,000

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Description

'Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date.

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Maximum Period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured senior notes, face value

'

'

'

'

'

'

150,000,000

'

150,000,000

500,000,000

'

500,000,000

'

Revolving credit facility outstanding balance

248,000,000

'

258,000,000

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Gross

'

'

'

'

'

'

150,000,000

150,000,000

'

497,400,000

497,200,000

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

2,600,000

2,800,000

3,100,000

'

Unsecured senior notes, fair value

'

'

'

'

'

'

$159,900,000

$165,400,000

'

$531,900,000

$558,300,000

'

$40,500,000

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 29, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	($2,858)	($3,017)
Foreign exchange derivative liabilities, net	-207	-294
Marketable securities	1,220	1,149
Foreign exchange derivative assets, net	246	274
Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	0	0
Foreign exchange derivative liabilities, net	0	0
Marketable securities	1,220	1,149
Foreign exchange derivative assets, net	0	0
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	0	0
Foreign exchange derivative liabilities, net	-207	-294
Marketable securities	0	0
Foreign exchange derivative assets, net	246	274
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	-2,858	-3,017
Foreign exchange derivative liabilities, net	0	0
Marketable securities	0	0
Foreign exchange derivative assets, net	$0	$0

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 30, 2012	Sep. 29, 2013	Sep. 30, 2012
Fair Value Disclosures [Abstract]	'	'	'	'
Balance beginning of period	($3,715)	($7,315)	($3,017)	($20,298)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	0	0	-1,100	0
Payments	31	3,771	95	17,417
Change in fair value (included within selling, general and administrative expenses)	826	2,338	1,164	1,675
Balance end of period	($2,858)	($1,206)	($2,858)	($1,206)

Leases_Details

Leases (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Aug. 22, 2013
Leases [Abstract]	'	'
Sale Leaseback Transaction, Date	'8/22/2013	'
Sale Leaseback Transaction, Gross Proceeds	$49.50	'
Sale Leaseback Transaction, Lease Terms	'P15Y	'
Sale Leaseback Transaction, Description of Accounting for Leaseback	'The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years.	'
Minimum Lease Payments, Sale Leaseback Transactions, Next Twelve Months	3.2	'
Minimum Lease Payments, Sale Leaseback Transactions, within Two Years	3.2	'
Minimum Lease Payments, Sale Leaseback Transactions, within Three Years	3.3	'
Minimum Lease Payments, Sale Leaseback Transactions, within Four Years	3.4	'
Minimum Lease Payments, Sale Leaseback Transactions, within Five Years	3.5	'
Minimum Lease Payments, Sale Leaseback Transactions, Thereafter	37.6	'
Sale Leaseback Transaction, Deferred Gain, Gross	'	26.5
Sale Leaseback Transaction, Cumulative Gain Recognized	0.2	'
Sale Leaseback Transaction, Deferred Gain, Net	$26.30	'

Contingencies_Details

Contingencies (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013
	years
Commitments and Contingencies Disclosure [Abstract]	'
Management's estimate of total cost of ultimate disposition	$6.90
Number of years over which estimated environmental cost will be paid	10